4D Molecular Thera

$11.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About 4D Molecular Thera

4D Molecular Therapeutics, Inc. is a development stage gene therapy company. The Company is focused on the development of targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). The Company product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.

Stock Analysis

last close $11.48
1-mo return 64%
3-mo return 4.4%
avg daily vol. 155.12T
52-week high 36.14
52-week low 5.32
market cap. $371M
forward pe -
annual div. -
roe -30.2%
ltg forecast -
dividend yield -
annual rev. $17M
inst own. 89.9%

Subscribe now for daily local and international financial news